Valuation: Adimmune Corporation

Market Cap 7.25B 222M 199M 183M 166M 310M 21.1B 316M 2.18B 876M 11.1B 834M 816M 35B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 7.25B 222M 199M 183M 166M 310M 21.1B 316M 2.18B 876M 11.1B 834M 816M 35B EV / Sales 2026 *
4.79x
EV / Sales 2027 * 4.32x
Free-Float
76.85%
Yield 2026 *
-
Yield 2027 * -
1 day-1.71%
1 week-3.37%
Current month-5.75%
1 month-5.75%
3 months+3.93%
6 months-2.82%
Current year-9.23%
1 week 17.2
Extreme 17.2
17.85
1 month 17.2
Extreme 17.2
19.5
Current year 16.4
Extreme 16.4
21.5
1 year 16.4
Extreme 16.4
22.5
3 years 15.9
Extreme 15.9
36.6
5 years 15.9
Extreme 15.9
48.85
10 years 15.9
Extreme 15.9
79.8
Manager TitleAgeSince
Chief Executive Officer - 20/06/2019
Director of Finance/CFO - 01/01/2021
Chief Tech/Sci/R&D Officer - 26/01/2022
Director TitleAgeSince
Director/Board Member - 20/06/2019
Director/Board Member - 15/08/2011
Director/Board Member - 29/06/2017
Change 5-day change 1-year change 3-year change Capi.($)
-1.71%-3.37%-9.23%-46.42% 222M
+3.19%+11.31%+67.86%+150.58% 1,263B
-0.73%+3.56%+44.51%+85.81% 658B
+1.41%+3.24%+29.22%+107.83% 521B
+0.42%+3.20%+54.15%+67.18% 391B
+2.18%+2.93%+73.30%+45.62% 369B
+1.12%+4.52%+35.30%+58.08% 307B
+6.96%+8.86%+11.27%+36.62% 290B
+1.15%+6.09%+59.59%+77.06% 252B
+3.06%+9.38%+44.11%+119.47% 212B
Average +1.39%+4.97%+41.01%+70.18% 426.22B
Weighted average by Cap. +1.19%+6.60%+50.88%+98.31%

Financials

2026 *2027 *
Net sales 1.52B 46.43M 41.58M 38.25M 34.66M 64.78M 4.41B 66M 456M 183M 2.32B 174M 171M 7.31B 1.68B 51.39M 46.03M 42.34M 38.36M 71.71M 4.88B 73.05M 505M 203M 2.57B 193M 189M 8.1B
Net income - -
Net Debt - -
Projected Income Statement - Annual - Adimmune Corporation
Logo Adimmune Corporation
Adimmune Corp is a Taiwan-based company mainly engaged in the research, development, processing, manufacturing, and sales of serums, vaccines, diagnostic reagents, biological agents, bacterial cultures, and raw materials. The Company's main products are influenza vaccines and non-influenza vaccines. Tetanus vaccines are used to prevent tetanus. Influenza vaccines are used to prevent seasonal influenza viruses. Tuberculin skin tests are used to determine whether a patient is infected with Mycobacterium tuberculosis. The Company primarily sells its products domestically and internationally.
Employees
564
Date Price Change Volume
30/10/26 NT$17.20 -1.71% 964,365
29/10/26 NT$17.50 0.00% 388,288
28/10/26 NT$17.50 -0.28% 419,124
27/10/26 NT$17.55 -1.40% 570,800
22/10/26 NT$17.80 -0.56% 328,730
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Adimmune Corporation
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
17.20TWD
Average target price
21.00TWD
Spread / Average Target
+22.09%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Adimmune Corporation
  1. Stock Market
  2. Stocks
  3. 4142 Stock